Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Screening and treatment of endocrine hypertension focusing on adrenal gland disorders: a narrative review

  • Seung Min Chung (Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine)
  • Received : 2024.07.19
  • Accepted : 2024.09.03
  • Published : 2024.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Most cases of high blood pressure have no identifiable cause, termed essential hypertension; however, in approximately 15% of cases, hypertension occurs due to secondary causes. Primary aldosteronism (PA) and pheochromocytoma and paraganglioma (PPGL) are representative endocrine hypertensive diseases. The differentiation of endocrine hypertension provides an opportunity to cure and prevent target organ damage. PA is the most common cause of secondary hypertension, which significantly increases the risk of cardiovascular disease compared to essential hypertension; thus, patients with clinical manifestations suggestive of secondary hypertension should be screened for PA. PPGL are rare but can be fatal when misdiagnosed. PPGL are the most common hereditary endocrine tumors; therefore, genetic testing using next-generation sequencing panels is recommended. Herein, we aimed to summarize the characteristic clinical symptoms of PA and PPGL and when and how diagnostic tests and treatment strategies should be performed.

Keywords

References

  1. Korean Society of Hypertension, Hypertension Epidemiology Research Working Group. Korea hypertension fact sheet 2022 [Internet]. Seoul: Korean Society of Hypertension; 2022 [cited 2024 Jul 15]. https://drive.google.com/file/d/1s2OROEH_OaUyI-h97DvAhOGP-oUtn2nX/view?usp= sharing.
  2. Young Jr WF, Calhoun DA, Lenders JW, Stowasser M, Textor SC. Screening for endocrine hypertension: an endocrine society scientific statement. Endocr Rev 2017;38:103-22.
  3. Kotchen TA. Hypertension. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL, editors. Harrison's principles of internal medicine. 21st ed. New York, NY: McGraw-Hill Education; 2022.
  4. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014;35: 1245-54.
  5. Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med 2019;285: 126-48.
  6. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017;69:1811-20.
  7. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004;89:1045-50.
  8. Mulatero P, Monticone S, Burrello J, Veglio F, Williams TA, Funder J. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J Hypertens 2016;34:2253-7.
  9. Choy KW, Fuller PJ, Russell G, Li Q, Leenaerts M, Yang J. Primary aldosteronism. BMJ 2022;377:e065250.
  10. Vaidya A, Mulatero P, Baudrand R, Adler GK. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev 2018;39:1057-88.
  11. Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018;6:41-50.
  12. Burrello J, Monticone S, Losano I, Cavaglia G, Buffolo F, Tetti M, et al. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension 2020;75:1025-33.
  13. Ha J, Park JH, Kim KJ, Kim JH, Jung KY, Lee J, et al. 2023 Korean Endocrine Society consensus guidelines for the diagnosis and management of primary aldosteronism. Endocrinol Metab (Seoul) 2023;38:597-618.
  14. Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro MC, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens 2020;38:1919-28.
  15. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016;101: 1889-916.
  16. Whelton PK, Carey RM, Mancia G, Kreutz R, Bundy JD, Williams B. Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/ Hypertension Guidelines. Eur Heart J 2022;43:3302-11.
  17. Kim HL, Lee EM, Ahn SY, Kim KI, Kim HC, Kim JH, et al. The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension. Clin Hypertens 2023;29:11.
  18. Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens 2012;26: 281-7.
  19. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45: 1243-8.
  20. Seccia TM, Letizia C, Muiesan ML, Lerco S, Cesari M, Bisogni V, et al. Atrial fibrillation as presenting sign of primary aldosteronism: results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study. J Hypertens 2020;38:332-9.
  21. Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995;13(12 Pt 2):1801-2.
  22. Notsu M, Yamauchi M, Yamamoto M, Nawata K, Sugimoto T. Primary aldosteronism as a risk factor for vertebral fracture. J Clin Endocrinol Metab 2017;102:1237-43.
  23. Monticone S, Sconfienza E, D'Ascenzo F, Buffolo F, Satoh F, Sechi LA, et al. Renal damage in primary aldosteronism: a systematic review and meta-analysis. J Hypertens 2020;38:3-12.
  24. Faconti L, Kulkarni S, Delles C, Kapil V, Lewis P, Glover M, et al. Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society. J Hum Hypertens 2024;38:8-18.
  25. Stowasser M, Ahmed AH, Cowley D, Wolley M, Guo Z, McWhinney BC, et al. Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2018;103:4113-24.
  26. Kwon SY, Park J, Park SH, Cho SH, Lee YB, Lee SY, et al. Aldosterone immunoassay-specific cutoff value for seated saline suppression test for diagnosing primary aldosteronism. Endocrinol Metab (Seoul) 2022;37:938-42.
  27. Thuzar M, Young K, Ahmed AH, Ward G, Wolley M, Guo Z, et al. Diagnosis of primary aldosteronism by seated saline suppression test-variability between immunoassay and HPLC-MS/MS. J Clin Endocrinol Metab 2020;105:e477-83.
  28. Luther JM, Turcu AF. Unilaterally successful adrenal vein sampling: use or repeat? Hypertension 2023;80:2014-6.
  29. Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 2011;58:797-803.
  30. Tetti M, Brudgam D, Burrello J, Udager AM, Riester A, Knosel T, et al. Unilateral primary aldosteronism: long-term disease recurrence after adrenalectomy. Hypertension 2024;81:936-45.
  31. Harris DA, Au-Yong I, Basnyat PS, Sadler GP, Wheeler MH. Review of surgical management of aldosterone secreting tumours of the adrenal cortex. Eur J Surg Oncol 2003;29:467-74.
  32. Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013;62:62-9.
  33. Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endres S, et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol 2012;168:75-81.
  34. Williams TA, Lenders JW, Mulatero P, Burrello J, Rottenkolber M, Adolf C, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017;5:689-99.
  35. Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med 1999;131:105-8.
  36. Cohen JB, Bancos I, Brown JM, Sarathy H, Turcu AF, Cohen DL. Primary aldosteronism and the role of mineralocorticoid receptor antagonists for the heart and kidneys. Annu Rev Med 2023;74:217-30.
  37. Sehgal R, Singh H, Singh IP. Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver. Eur J Gastroenterol Hepatol 2020;32:535-9.
  38. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
  39. de Gasparo M, Whitebread SE, Preiswerk G, Jeunemaitre X, Corvol P, Menard J. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989;32(1B):223-7.
  40. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Barfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014;64:69-78.
  41. Dojki FK, Bakris G. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens 2017;26:368-74.
  42. Li Q. Efficacy and safety of finerenone in patients with primary aldosteronism. ClinicalTrials.gov ID: NCT05924620 [Internet]. Bethesda, MD: National Library of Medicine; 2024 [cited 2024 Jul 19]. https://clinicaltrials.gov/study/NCT05924620.
  43. Li Q. Finerenone for Patients With Primary Aldosteronism (FAIRY). ClinicalTrials.gov ID: NCT06457074 [Internet]. Bethesda, MD: National Library of Medicine; 2024 [cited 2024 Jul 19]. https://clinicaltrials.gov/study/NCT06457074.
  44. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 2018; 72:e53-90.
  45. Kantorovich V, Pacak K. Pheochromocytoma and paraganglioma. Prog Brain Res 2010;182:343-73.
  46. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915-42.
  47. Eisenhofer G. Screening for pheochromocytomas and paragangliomas. Curr Hypertens Rep 2012;14:130-7.
  48. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005;366:665-75.
  49. Canu L, Parenti G, De Filpo G, Mannelli M. Pheochromocytomas and paragangliomas as causes of endocrine hypertension. Front Endocrinol (Lausanne) 2019;10:333.
  50. Melson E, Amir S, Shepherd L, Kauser S, Freestone B, Kempegowda P. Myocardial Infarction with non-obstructed coronaries: atypical presentation of pheochromocytoma. Endocrinol Diabetes Metab Case Rep 2019;2019:EDM190089.
  51. Lee YY, Chung SM. Interleukin-6-producing paraganglioma as a rare cause of systemic inflammatory response syndrome: a case report. J Yeungnam Med Sci 2023;40:435-41.
  52. Gruber LM, Hartman RP, Thompson GB, McKenzie TJ, Lyden ML, Dy BM, et al. Pheochromocytoma characteristics and behavior differ depending on method of discovery. J Clin Endocrinol Metab 2019;104:1386-93.
  53. Young WF Jr. Clinical presentation and diagnosis of pheochromocytoma [Internet]. Waltham, MA: UpToDate; 2024 [cited 2024 Jul 19]. https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-heochromocytoma.
  54. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 1998;83:2175-85.
  55. Peaston RT, Graham KS, Chambers E, van der Molen JC, Ball S. Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma. Clin Chim Acta 2010;411:546-52.
  56. Mullins F, O'Shea P, FitzGerald R, Tormey W. Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal. Clin Chem Lab Med 2011;50:105-10.
  57. Neary NM, King KS, Pacak K. Drugs and pheochromocytoma: don't be fooled by every elevated metanephrine. N Engl J Med 2011;364:2268-70.
  58. Leow MK, Loh KC, Kiat Kwek T, Ng PY. Catecholamine and metanephrine excess in intracerebral haemorrhage: revisiting an obscure yet common "pseudophaeochromocytoma". J Clin Pathol 2007;60:583-4.
  59. Grouzmann E, Drouard-Troalen L, Baudin E, Plouin PF, Muller B, Grand D, et al. Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma. Eur J Endocrinol 2010; 162:951-60.
  60. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003;88:553-8.
  61. Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 1994;15: 356-68.
  62. Canu L, Van Hemert JA, Kerstens MN, Hartman RP, Khanna A, Kraljevic I, et al. CT Characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma. J Clin Endocrinol Metab 2019;104:312-8.
  63. Ku EJ, Kim KJ, Kim JH, Kim MK, Ahn CH, Lee KA, et al. Diagnosis for pheochromocytoma and paraganglioma: a joint position statement of the Korean Pheochromocytoma and Paraganglioma Task Force. Endocrinol Metab (Seoul) 2021;36:322-38.
  64. Neumann HP, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med 2019;381:552-65.
  65. Muth A, Crona J, Gimm O, Elmgren A, Filipsson K, Stenmark Askmalm M, et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med 2019;285:187-204.
  66. Fang F, Ding L, He Q, Liu M. Preoperative management of pheochromocytoma and paraganglioma. Front Endocrinol (Lausanne) 2020;11:586795.
  67. Lenders JW, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 2020;38:1443-56.
  68. Sibal L, Jovanovic A, Agarwal SC, Peaston RT, James RA, Lennard TW, et al. Phaeochromocytomas presenting as acute crises after beta blockade therapy. Clin Endocrinol (Oxf) 2006;65: 186-90.
  69. Wang L, Zeng W, Wu Y, Gong Z. Comparison of clinical efficacy and safety between robotic-assisted and laparoscopic adrenalectomy for pheochromocytoma: a systematic review and meta-analysis. J Robot Surg 2024;18:115.
  70. Ilanchezhian M, Jha A, Pacak K, Del Rivero J. Emerging treatments for advanced/metastatic pheochromocytoma and paraganglioma. Curr Treat Options Oncol 2020;21:85.
  71. FDA approves AZEDRA specified use in pheochromocytomas/paragangliomas. J Nucl Med 2018;59:17N.
  72. Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med 2019;60:623-30.
  73. Thorpe MP, Kane A, Zhu J, Morse MA, Wong T, Borges-Neto S. Long-term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131-I MIBG. J Clin Endocrinol Metab 2020;105:e494-501.
  74. O'Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ, et al. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer 2019;120:1113-9.
  75. Baudin E, Goichot B, Berruti A, Hadoux J, Moalla S, Laboureau S, et al. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. Lancet 2024;403:1061-70.
  76. Plouin PF, Amar L, Dekkers OM, Fassnacht M, GimenezRoqueplo AP, Lenders JW, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. EurJ Endocrinol 2016;174:G1-10.